Figure 1.

Characterization of Genetically Engineered PD1ACR and PDL1CAR T Cells

(A) Schematic representation of a bicistronic lentiviral vector expressing ACR and CAR. (B) PD-1-specific ACR (PD1ACR) and αPDL1-specific CAR (PDL1CAR) expression levels on human T cells transduced with lentiviral particles were analyzed using flow cytometric antibodies anti-human PD-1 and anti-human IgG by detecting PD-1 and αPDL1 expression, respectively. Transduction efficiencies are shown inside each panel. (C) Additional features of PD1ACR-T and PDL1CAR-T cells that combat the PD-L1-expressing solid cancers. (D) A sandwich ELISA was performed to evaluate the binding ability of PD1ACR and PDL1CAR to human PD-L1 by using PD1ACR-, PDL1CAR-, and mock-transduced 293T cells. Untransduced 293T cells were employed as a negative control (blank) (∗∗p < 0.01). (E) Expression percentages plotted in bars and cell fold changes expressed in line plots of PD1ACR/PDL1CAR cells, presented as the mean ± SD, were derived from three independent healthy donors during a 2-week culture period in the stimulation of recombinant human PD-L1 Fc protein.